The anti-p185 her2/neu peptidomimetic (AHNP) is a small exo-cyclic peptide derived from the anti-p185 her2/neu rhumAb 4D5 (h4D5). AHNP mimics many but not all of the antitumor characteristics exhibited by h4D5. However, the pharmacokinetic profiles of AHNP are less than optimal for therapeutic or diagnostic purposes. To improve the binding affinity to p185
Introduction
Monoclonal antibodies represent mainstream agents for molecular diagnosis and have recently become de facto cancer therapeutics. There is a great interest in developing smaller versions of therapeutic antibodies for several reasons: namely to improve tumor penetration, eliminate the humanization process, and reduce the cost of production (Maynard and Georgiou, 2000; Hudson and Souriau, 2003) . Previously, we established a general principle that a single CDR3 loop from the heavy chain of an antibody is sufficient to mimic its parental monoclonal antibody function (Murali and Greene, 1998) . The CDR peptide is much smaller than the antibody but retains binding affinity to the antigen as well as the biological activity of the antibody. Our studies with CDR mimetics demonstrated that the constrained CDRs could mediate binding in a contextindependent manner and formed the theoretical basis for the technique of CDR grafting (Bruck et al., 1986; Williams et al., 1989; Park et al., 2000) . p185 her2/neu (Her2, Neu, c-ErbB2) is overexpressed in many breast and ovarian cancers (Slamon et al., 1989) , lung tumors (Kern et al., 1990) as well as tumors of the pancreas (Williams et al., 1991) . Extensive studies have shown that p185 her2/neu plays a dominant role in mediating the malignant phenotype (Kokai et al., 1988; Cohen et al., 1989; Lodato et al., 1990) . The evolution of targeted therapy began with the development of monoclonal antibodies to p185 her2/neu (Drebin et al., 1984 (Drebin et al., , 1985 (Drebin et al., , 1986 (Drebin et al., , 1988 that directly lead to the reversion of the malignant phenotype. The anti-p185 her2/neu antibody 'trastuzumab' (h4D5 or Herceptin, Genentech, San Francisco, CA, USA), which represented a humanized antibody of similar specificity, has been approved by FDA to treat breast cancers (Sliwkowski et al., 1999) .
Earlier, we reported the design of a p185 her2/neu binding peptidomimetic (BiP) anti-p185 her2/neu peptidomimetic (AHNP) (FCDGFYACYMDV) (Park et al., 2000; Berezov et al., 2001) . AHNP was rationally derived from the structure of the CDR-H3 loop of the antip185 her2/neu antibody h4D5, and possessed the ability to disable p185
her2/neu tyrosine kinase activity in vitro and in vivo similar to, but with far less affinity, than the monoclonal antibody. Unlike the intact phenotypereverting monoclonals, AHNP was unable to downregulate p185 her2/neu from the cell surface, indicating that the small molecule functioned to directly disable the p185 her2/neu complex. These characteristics suggested a potential for antibody-mimicking peptidomimetics to serve as reagents for tumor therapy.
Streptavidin (SA), a tetrameric protein produced by Streptomyces avidinii that binds to biotin with an extremely high affinity (K D B10 À15 M), represents an ideal scaffold to enhance the functional potential of AHNP. With a high affinity for biotin, the fusion protein will be able to carry biotinylated therapeutics (such as cytotoxins) or labeling reagents to tumor cells with p185
her2/neu overexpression. This strategy has already been tested on antibody-SA conjugates but the results are varied due to the large size of the antibody (Kalofonos et al., 1990) . In addition, the new class of CDR-carrying tetramers can also be used to replace antibodies in assays utilizing the biotin-SA system. In fact, the ASA can be also used as a diagnostic tool to detect p185 her2/neu in early breast cancer developments using FACTT, an ultra-sensitive detection technology (Zhang et al., 2006) . Third, the in vivo pharmacokinetics of SA have been well studied (Rosebrough, 1993) and SA constructs have been used in patients (Kalofonos et al., 1990) . However, the therapeutic characteristics of functional peptidomimetics fused to nonimmunoglobulin protein scaffolds are not known.
In the present study, we have recombinantly fused the AHNP peptide to SA. Here, we show that ASA possesses the abilities to bind the p185 her2/neu ectodomain and to suppress the proliferation of p185 her2/neu -transformed cells in vitro as well as in vivo. These studies serve as a principle to create new forms of antibody-surrogate molecules in a modular fashion. Biologically active peptides can be linked to a suitable scaffold upon which multiple copies of relevant CDRs are disposed. We have termed the new species, which contains a functional CDR peptide loop on a nonimmunoglobulin scaffold, a 'Multimeric Binding peptide (mBip)'.
Results
Expression and purification of the ASA in Escherichia coli In ASA, a flexible 11 amino-acid (a.a.) linker (GGGGSRSNSSS) connects the AHNP unit to the N-terminus of the SA core. ASA also contains a 6 Â His tag for the purification purpose. While SA was easily expressed as a soluble protein in Escherichia coli (E. coli), ASA was insoluble and formed inclusion bodies ( Figure 1a ). Insoluble ASA was dissolved in guanidine hydrochloride under reducing conditions, refolded and purified by Co 2 þ resin under oxidative conditions. On Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), both SA and ASA revealed a single band of B16 kDa, with ASA at a slightly higher position, after the proteins were heated at 1001C (lanes 1, 3; Figure 1b) . The observed sizes correlate with the expected molecular weight of monomers. Under milder conditions (heated at 551C, in the absence of 2-ME), SA and ASA appeared as a single band of B64 kDa (lanes 2, 4; Figure 1b ), indicating that these proteins associate as tetramers.
A disulfide bond was designed to form between the two cysteines in the AHNP sequence. In antibodyderived peptides or proteins, disulfide bonds are essential to constrain the mimetic peptides (Park et al., 2000) and also play a critical role in maintaining the structural framework required for binding to antigens (Proba et al., 1997; Jurado et al., 2002) . We chose the sulfhydryl-alkylating reagent 4-acetamide-4 0 -maleimidylatylbene-2,2 0 -disulfonic acid (AMS, M r B500 Da) to determine if the fusion proteins form the required disulfide bonds. Reduced proteins bind to AMS covalently with free thiol groups and migrated as molecules of higher molecular weight in nonreducing SDS-PAGE. As shown in Figure 2 , ASA expressed in bacteria was reduced and bound to AMS independent of dithiothreitol (DTT) treatment. This is due to the reducing environment in the E. coli cytoplasm. After purification, ASA was oxidized and only bound to AMS if pretreated with DTT. Since SA has no cysteines, AMS did not affect the mobility of SA on the SDS-PAGE (Figure 2c ). Our data suggest that the purification procedure facilitated proper disulfide bond formation in ASA.
To verify whether ASA is refolded properly, we studied its binding to biotin and p185 her2/neu by enzyme-linked immunosorbent assays (ELISA). Using biotin-coated microplates, we found that both SA and ASA bound to biotin in a dose-dependent manner Formation of tetramers observed in purified ASA and SA. Lanes 1 and 3, purified proteins were heated for 5 min in boiling water in the presence of SDS, DTT and 2-ME; Lanes 2 and 4, samples were heated for 5 min at 551C in the presence of SDS and DTT without 2-ME. Lanes 1 and 2, SA: Lanes 3 and 4, ASA.
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her2/neu protein ASA K Masuda et al ( Figure 3a ). In a separate experiment, ASA was able to bind to the Her2-Fc fusion in a dose-dependent manner, while SA demonstrated no binding even at the highest concentration ( Figure 3b ). These data indicate that the ASA retains a native structure, which permits an integrated biophysical activity of AHNP and SA.
Kinetic analysis of ASA binding to HER2 AHNP-SA (ASA) was also tested for binding to the HER2 receptor ectodomain by Biacore 3000 (Biacore International AB, Sweden). Kinetic constants were estimated by global fitting analysis of the sensor gram curves to the 1:1 Langmuirian interaction model, which gave a k on of 2.09 Â 10 5 M À1 s À1 , and a k off of 1.83 Â 10 À3 s À1 . The k off /k on ratio gave a value of 8.8 nM for the equilibrium dissociation constant (K D ). The apparent affinity of ASA is about 40-fold higher than AHNP (350 nM), suggesting that ASA might be useful for diagnostic and therapeutic purposes.
Biological activity of the ASA Next, we determined if ASA could inhibit proliferation of p185 her2/neu -transformed T6-17 cells (Di Fiore et al., 1987) . Treatment with ASA fusion proteins at two different concentrations resulted in 20-50% inhibition of cell proliferation in a dose-dependent manner ( Figure 4a ). Inhibitory effects were not observed in the control NR6 cell line ( Figure 4b ). However, compared with the AHNP peptide in molar concentration, more ASA (about 2.5 times) was required to achieve 50% cell growth inhibition in vitro. Both ASA and AHNP were less potent than h4D5 in the inhibition of the anchorageindependent growth of T6-17 in the polyHEMA plate assay.
In vivo activity
We have established a mouse tumor model using the transformed T6-17 cells. After T6-17 cells are inoculated into nude mice subcutaneously (s.c.), palpable tumors appear after about 48-72 hours. To assess ASA as a protein therapeutic, we treated animals with either SA alone or ASA (3.75 mg/kg/dose, three times per week). Treatment started from day 0 and was provided to animals by three s.c. injections each week. Treatment with ASA prevented the appearance of palpable tumors until day 7 and reduced the tumor size by 62% at day 14 ( Figure 5a ).
We also studied in vivo ASA activity by intraperitoneal (i.v.) administration. Treatment, started day 3 after palpable tumors appeared (B2 cm 3 ) was also provided to animals by three injections per week (Figure 5b-c) . Consistently, ASA demonstrated inhibition of tumor growth in a dose-dependent manner (Figure 5b ). ASA (5 mg/kg, or 80 nmol/kg/dose) demonstrated 40 times greater activity than the peptidomimetic AHNP (4 mg/kg, or 3 mmol/kg/dose) (Figure 5c ), suggesting that the pharmacokinetics of ASA is superior to AHNP and is critical for in vivo activity. The result with ASA Figure 2 Disulfide bond formation in ASA and SA. AMS-alkylation was used to determine if disulfide bonds were formed in ASA produced in the cytoplasm of E. coli BL21(LysE) and after refolding. The alkylated and nonalkylated products, representing reduced and oxidized forms, respectively, were separated by their different mobility in nonreducing SDS-PAGE and visualized by Western blot probed with anti-SA antibody. 
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Discussion
After we rationally designed the CDR exocyclic peptide, which mimics antibody function (Park et al., 2000), we explored ways to both enhance the binding profile and extend therapeutic potentials of the peptide AHNP. We have developed the notion that a multivalent CDR exocyclic peptide might enhance its biological potential.
To verify this idea, we have engineered a novel fusion protein, ASA. As we expected, ASA forms a tetramer after being recombinantly expressed and refolded. The high affinity of ASA for p185 her2/neu and biotin suggests that this fusion protein is properly folded to retain its biological functions.
ASA exhibits 40-fold higher affinity to p185 To determine the disposition of AHNP in ASA, we have partially resolved the three-dimensional structure 
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her2/neu protein ASA K Masuda et al of ASA by X-ray crystallography at 2.8 Å . A detailed report on the crystal structure of ASA will be published elsewhere. Briefly, AHNP and the 11 a.a. linker in ASA are structurally disordered and not visible in the electron density map. However, the approximate position of AHNP can be located based on the crystal packing restraints. Two SA monomers in the asymmetric unit form a dimer (A-B) and are related by the noncrystallographic twofold symmetry. This dimer then associates with its symmetry (twofold axis)-related molecule, forming a tetramer (A-B-A 0 -B 0 ) (Figure 6 ). The Nterminal AHNP units of the A-B dimer are directed to two opposite directions. Hence, it is unlikely that the two AHNP units in A-B dimer can interact with the same p185 her2/neu structure (either homo-or hetero-dimer) simultaneously. However, the N-terminus of A and A 0 point in the same direction to position the two AHNP peptides adjacent to each other (35 Å ). The same is true of the two AHNP units in B and B 0 (25 Å ). Thus, it appears that the tetrameric molecule contains two separate p185 her2/neu -binding surfaces, each consisting of two copies of AHNP units. The tetramer really functions as two dimers.
ASA displays activity in vitro and in vivo. Surprisingly, ASA demonstrated less antiproliferative activity than the AHNP peptide in vitro in an anchorage-independent assay using polyHEMA, but was about 40-fold more active than AHNP in reducing tumor growth in vivo. These studies reaffirm the notion that in vitro assays of malignant phenotype are never as revealing as in vivo tumor growth. Earlier while developing the AHNP species, we found that the in vitro biological activity of peptidomimetic correlated with its slow dissociation rate of binding (Berezov et al., 2001) . It is possible that in the cell-based assay condition, ASA binding to the receptor is weak owing to the long flexible linkers between AHNP and SA. This is clearly reflected in the SPR studies, in which the AHNP disassociation rate is comparable to antibody (in the order of 10 À4 ), while ASA disassociates is slightly faster than AHNP.
In vivo, ASA consistently exhibited potent antitumor activity. Recombinantly produced ASA showed a comparable antitumor effect (50-60% inhibition) as the antibody (h4D5) and had a much higher activity than AHNP. Considering the observation that AHNP has better activity than ASA in vitro, the results observed in vivo suggest that the reduced biological activity of AHNP is related to its pharmacokinetics and not due its binding affinity. Although we have not obtained data on the ASA pharmacokinetics yet, we expect ASA to have a serum half-life close to that of SA (12 h) (Rosebrough, 1993) since they have similar core structure and molecular weight. In comparison, AHNP only has a serum half-life of about 2-3 h.
In separate studies we have found that several anti-p185 her2/neu antibodies can promote tetrameric receptor complexes, which are less kinase active and primed for the receptor downregulation (Furuuchi et al., manuscript submitted). Based on these observations, we hypothesize that ASA might promote signalingdefective receptor ensembles. These signaling-defective receptor ensembles (inactive tetrameric complexes) might be functionally similar to defective dimers induced by AHNP. We can extend these scaffolds to other polymerizing molecules. Thus, AHNP fusions with dimeric, trimeric or tetrameric scaffolds such as helical bundles may create species suitable for human therapeutic and diagnostic applications.
In summary, our study has demonstrated a rational protein engineering approach to produce in bacteria therapeutically useful fusions carrying anti-p185 her2/neu peptide, AHNP. The bacterial system is the most inexpensive expression system for recombinant proteins. Bacterially expressed ASA has an economic benefit compared to Herceptin. ASA also has the potential of replacing antibodies in the tumor-imaging field. In the most successful two-step tumor imaging procedure (Kalofonos et al., 1990) , the antibody has to be linked to SA first before it can be used in a pretarget step. ASA, with full biotin-binding activity of SA, is completely compatible with such a two-step system. With engineered SA of lower immunogenicity (Chinol et al., 1998; Meyer et al., 2001) , ASA can be used to deliver biotinylated therapeutics, such as toxins or heavy metals, to enhance its in vivo activity. Finally, the advantage of our approach is that the construct is modular. Small peptide mimetics remain as functional units but linked to the scaffolds to render bioactive peptides into useful therapeutics that can be expressed inexpensively in bacteria. 
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Materials and methods
Cell lines T6-17 (gift from Dr JH Pierce) was derived from NIH3T3 by overexpressing the p185 her2/neu receptor (Di Fiore et al., 1987) . NR6 is a mouse fibroblast cell line that lacks endogenous EGF receptors. T6-17 and NR6 cells were grown in Dulbecco's modified Eagle medium supplemented with 10% heat inactivated fetal calf serum, L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml) at 371C in a humidified 5% CO 2 atmosphere.
Construction of plasmids
Two plasmids, pKMSH and pKMASH, were constructed to express SA and ASA fusion protein, respectively, under the control of T7 promoter and lacIq. The following primers were used to clone SA or the fusion protein: For SA, primer19 (5 0 -AAAAAACATATGGAAGCAGGTATCACCGGCACA CCTGGTACAACCAGCTCGGCTCGACCTTCATCGTGA CCGCGGC-3 0 ) and primer3-2dch (5 0 -AAGCTTTTATTA ATGATGATGGTG-ATGATGG-3 0 ); for AHNP fusion protein ASA, primer1 (5 0 -AAAAAACATATGGTCGACTAT TGCGATGGCTTTTATG CGTGCTATATGGATGTGGG TGGTGGTGGTAG-3 0 ), primer2 (5 0 -GGATGTGGGTGGT GGTGGTAGCAGATCTAACAGCAGCAGCGAAGCAG GTATCACCGGACAATGGTACAC-3 0 ) and primer3-2dch. The amplified DNAs were ligated to pCR2.1 vector using the TA Cloning Kit (Invitrogen, Carlsbad, CA, USA). The plasmid pKMSH was constructed by inserting the core sequence of SA into the NdeI and HindIII restriction sites of pET21 (a) þ . pKMSH was then used as a platform for the construction of the ASA fusion protein expression vector pKMASH. Two restriction enzyme sites (SalI and BglII) were engineered at the N-terminus of AHNP and inside the linker, respectively, for the convenience of replacing the AHNP sequence in the future.
Fusion protein production, cyclization and purification E. coli BL21 Origami (LysS) (Novagen) cells harboring either pKMSH or pKMASH were grown with 50 mg/ml ampicillin at 251C. When the OD at 600 nm reached 0.4, SA and ASA were induced to express with 0.5 mM isopropyl b-D-thiogalactopyranoside (IPTG) and cultured at 371C for 2.5 h. The recombinant proteins were insoluble and existed in the inclusion body. After cells were sonicated, the pellet (inclusion body fraction) was obtained by centrifugation at 10 000 g for 30 min and then solublized at 10 mg/ml with 100 mM Tris-Cl (pH 7.5), containing 6 M guanidine-HCl and 1 mM DTT. The supernatant was obtained by centrifugation at 10 000 g for 30 min and then diluted against 20 times volume of 100 mM Tris-Cl (pH 7.5), containing 1 mM reduced form glutathione and 0.1 mM oxidized form glutathione. After dilution, the supernatant was obtained by centrifugation at 10 000 g for 30 min and then incubated for 45 min at 41C with 1 ml of Talon resin (Clontech, Mountain View, CA, USA), which had been equilibrated with buffer A, composed of 100 mM Tris-Cl (pH 7.5) and 300 mM NaCl. The resin was packed into a column, and washed with 20 ml of buffer A and then 10 ml of buffer A supplemented with 30 mM imidazole. SA or ASA was eluted with buffer A containing 250 mM imidazole and dialysed against phosphate-buffered saline (PBS). Alternatively, insoluble fusion proteins were also solublized by urea (8 M), purified through a Ni-NTA agarose column (Qiagen), and refolded by stepwise reduction of urea in the dialysis buffer.
Determination of disulfide bond formation by protein alkylation with AMS Disulfide bond formation of ASA was determined by the AMS method described previously (Invitrogen) (Kobayashi and Ito, 1999) . Briefly, bacterial lysates (100 ml) or purified protein samples (2 mg) were treated with DTT (100 mM) for 10 min at 1001C. Proteins were then precipitated with trichloroacetic acid (TCA, 10% W/V) for 10 min at 41C. After centrifugation at 10 000 g for 15 min, the pellet was washed once with 250 ml of ice-cold acetone and air-dried after centrifugation again. Alkylation was performed in 20 ml of the buffer containing 150 mM Tris-Cl (pH 7.5), 2% SDS (W/V) and 15 mM AMS for 1 h at room temperature. 20 ml of SDS-PAGE sample buffer (2 Â ) lacking 2-mercaptoethanol was added to all samples, which were then analysed by SDS-PAGE and immunoblotting with horseradish peroxidase (HRP)-conjugated anti-SA antibody (Invitrogen, Carlsbad, CA, USA).
MTT assay
To measure cell proliferation, we used the modified anchorageindependent 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay as previously described (Hansen et al., 1989) . T6-17 cells (800 cells/well, poly 2-hydroxyethyl methacrylate (poly-HEMA) coated) or NR6 cells (1200 cells/ well) were seeded in 96-well plates in the presence of SA, ASA or the AHNP peptide and incubated at 371C in a humidified 5% CO 2 atmosphere for 48 h. A total of 25 ml of MTT solution (5 mg/ml in PBS) was added to each well, and after 2 h of incubation at 371C, 100 ml of the extraction buffer (20% w/v SDS, 50% N,N-dimethyl formamide, pH 4.7) was added. After an overnight incubation at 371C, the optical density at 570 nm was measured using an ELISA reader.
Enzyme-linked immunosorbent assays
The binding of ASA to biotin and p185 her2/neu was determined by an ELISA assay modified from the previously described method (Farlow et al., 2002) . Purified SA or ASA was immobilized on a biotin-coated ELISA plate (Pierce, Rockford, IL, USA) for 1 h at 41C in PBS. Excess protein was washed out and then 50 ng/well of purified Her2-human Fc fusion (Park et al., 2000) protein in PBS was added to each well. After a 3 h incubation at 41C, plates were washed 6 times with PBS containing 0.1% Tween-20 (PBS-T; 150 ml/well) and anti-p185 her2/neu antibody was added in PBS (1:500 dilution; 50 ml/well). After a 1 h further incubation, plates were washed six times with PBS (200 ml/well) and HRP-conjugated antimouse IgG antibody was added (1:5000 dilution; 50 ml/well). Finally, plates were washed six times with PBS (200 ml/well) and bound anti-mouse IgG antibody-HRP was developed using a substrate solution (100 ml/well) containing 3,3 0 ,5,5 0 -tetramethylbenzene (1 tablet/10 ml solution; Sigma, St Louis, MO, USA) in phosphate-citrate buffer (103 mM dibasic sodium phosphate, 24 mM citric acid, pH 5.0; Sigma). The reaction was allowed to proceed in the dark for 2 min at RT, and stopped with 2 M H 2 SO 4 (50 ml/well). A 450 readings of the samples were determined using an ELISA reader. Bound SA was detected by the same method using an anti-SA-HRP in PBS (1:500 dilution; 50 ml/well).
Study of ASA and p185
her2/neu interaction using the Biacore Binding experiments were performed with the surface plasmon resonance-based biosensor instrument Biacore 3000 (Biacore AB, Uppsala, Sweden), at 251C, as described previously (Berezov et al., 2002) . Immobilization of HER2 on the sensor surface was performed following the standard amine coupling procedure according to the manufacturer's instructions.
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her2/neu protein ASA K Masuda et al Briefly, 35 ml of a solution containing 0.2 M N-ethyl-N 0 -(dimethylaminopropyl) carbodiimide and 0.05 M N-hydroxysuccinimide, were injected at a flow rate of 5 ml/min to activate carboxyl groups on the sensor chip surface. HER2 (40 ng/ml in 10 mM sodium acetate buffer, pH 5.0) was flowed over the chip surface at a flow rate of 20 ml/min until the desired level of bound protein (2000 RU) was reached. Unreacted protein was washed out and activated groups that had not reacted were blocked by the injection of 35 ml of 1 M ethanolamine at 5 ml/ min. A reference surface was generated simultaneously under the same conditions but without receptor injection and used as a blank to correct for instrument and buffer artefacts. ASA was injected at variable concentrations at a 20 ml/min flow rate and binding to the HER2 receptor immobilized on the chip was monitored in real time as a series of sensor grams.
Mice NCR homozygous athymic (nude) mice (6 to 8-week-old) were purchased from the National Cancer Institute. To induce tumor formation, 10 6 transformed T6-17 cells were suspended in 100 ml of PBS and injected s.c. into the flank of each animal. Animals were maintained in accordance with guidelines of the Institutional Animal Care and Use Committee (IACUC) of the University of Pennsylvania. Tumor volume was calculated by the formula: p Â length Â width Â Height/6.
